Matthew Taylor
Stock Analyst at UBS
(2.69)
# 2,110
Out of 5,056 analysts
182
Total ratings
60%
Success rate
10.93%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Neutral | $320 → $355 | $336.84 | +5.39% | 16 | Nov 7, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $80 → $98 | $85.58 | +14.51% | 20 | Oct 29, 2025 | |
| SI Shoulder Innovations | Initiates: Buy | $19 | $15.00 | +26.67% | 1 | Aug 25, 2025 | |
| ABT Abbott Laboratories | Upgrades: Buy | $143 → $145 | $128.82 | +12.56% | 17 | Jul 18, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.61 | +2.67% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $74.98 | +37.37% | 2 | Jan 8, 2025 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $95.81 | -20.68% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $1.50 | +8,233.33% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $149.85 | -19.25% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $4.42 | +216.74% | 1 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $45 | $18.06 | +149.17% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $10 | $6.59 | +51.75% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $12.09 | +338.38% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $12.35 | +94.33% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $367.34 | -6.08% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $90.03 | +44.40% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $280.29 | -17.94% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $18.00 | +11.11% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $43.56 | +95.13% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $84.71 | -11.46% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $252.86 | -3.11% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $18.70 | +231.55% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $111.49 | +88.36% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $20.75 | -42.17% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $59.61 | +109.70% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $104.13 | -51.98% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $572.45 | -63.32% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $56.62 | +69.55% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $2.26 | +209.73% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $192.12 | +38.46% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $12.66 | +26.38% | 2 | Jul 19, 2017 |
Insulet
Nov 7, 2025
Maintains: Neutral
Price Target: $320 → $355
Current: $336.84
Upside: +5.39%
Edwards Lifesciences
Oct 29, 2025
Upgrades: Buy
Price Target: $80 → $98
Current: $85.58
Upside: +14.51%
Shoulder Innovations
Aug 25, 2025
Initiates: Buy
Price Target: $19
Current: $15.00
Upside: +26.67%
Abbott Laboratories
Jul 18, 2025
Upgrades: Buy
Price Target: $143 → $145
Current: $128.82
Upside: +12.56%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.61
Upside: +2.67%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $74.98
Upside: +37.37%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $95.81
Upside: -20.68%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $1.50
Upside: +8,233.33%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $149.85
Upside: -19.25%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $4.42
Upside: +216.74%
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $18.06
Upside: +149.17%
Jul 19, 2023
Initiates: Underperform
Price Target: $10
Current: $6.59
Upside: +51.75%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $12.09
Upside: +338.38%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $12.35
Upside: +94.33%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $367.34
Upside: -6.08%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $90.03
Upside: +44.40%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $280.29
Upside: -17.94%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $18.00
Upside: +11.11%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $43.56
Upside: +95.13%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $84.71
Upside: -11.46%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $252.86
Upside: -3.11%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $18.70
Upside: +231.55%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $111.49
Upside: +88.36%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $20.75
Upside: -42.17%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $59.61
Upside: +109.70%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $104.13
Upside: -51.98%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $572.45
Upside: -63.32%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $56.62
Upside: +69.55%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $2.26
Upside: +209.73%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $192.12
Upside: +38.46%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $12.66
Upside: +26.38%